Last 12 months
Inside the activity.
2 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 1 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 1 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 12,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · derivative · entry 7 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,625 Underlying: Common Stock · 12,312 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F5 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 36,937 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 6,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · derivative · entry 6 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,555 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F4 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 19,664 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F4 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 19,664 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC |
Stahler Rachel AChief Information Officer
|
GrantRestricted Stock Units · Derivative | 183,639 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · derivative · entry 5 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,639 Underlying: Common Stock · 183,639 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 183,639 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 4,217 | $5.70 | $24,036.90 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · nonDerivative · entry 4 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 116,105.292 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionCommon Stock | 12,312 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · nonDerivative · entry 3 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,322.292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC |
Stahler Rachel AChief Information Officer
|
Tax withholdingCommon Stock | 2,246 | $5.70 | $12,802.20 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · nonDerivative · entry 2 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,010.292 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:14 UTC |
Stahler Rachel AChief Information Officer
|
Exercise / conversionCommon Stock | 6,555 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023166 · wk-form4_1775160890.xml · nonDerivative · entry 1 Stahler Rachel A · CIK 0001679854 · Chief Information Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,256.292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionRestricted Stock Units · Derivative | 6,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · derivative · entry 7 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,432 Underlying: Common Stock · 6,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 20,147 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F5 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 20,147 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionRestricted Stock Units · Derivative | 11,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · derivative · entry 6 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,338 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F4 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 34,014 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F4 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 34,014 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
GrantRestricted Stock Units · Derivative | 100,166 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · derivative · entry 5 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,166 Underlying: Common Stock · 100,166 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 100,166 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 100,166 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 100,166 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Tax withholdingCommon Stock | 2,105 | $5.70 | $11,998.50 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · nonDerivative · entry 4 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 69,547.923 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionCommon Stock | 6,715 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · nonDerivative · entry 3 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,652.923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Tax withholdingCommon Stock | 3,554 | $5.70 | $20,257.80 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · nonDerivative · entry 2 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,937.923 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 16:17 UTC |
Karp DanielExecutive VP, Corp. Dev.
|
Exercise / conversionCommon Stock | 11,338 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023180 · wk-form4_1775161029.xml · nonDerivative · entry 1 Karp Daniel · CIK 0001744046 · Executive VP, Corp. Dev. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,491.923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:11 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 11,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023150 · wk-form4_1775160674.xml · derivative · entry 7 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,386 Underlying: Common Stock · 11,193 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 33,579 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining to vest on March 31, 2027 and March 31, 2028. F5 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 33,579 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:11 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023150 · wk-form4_1775160674.xml · derivative · entry 6 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,732 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F4 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 20,195 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F4 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 20,195 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:11 UTC |
Falcione AaronChief Human Resources Officer
|
GrantRestricted Stock Units · Derivative | 166,944 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023150 · wk-form4_1775160674.xml · derivative · entry 5 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,944 Underlying: Common Stock · 166,944 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 166,944 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 166,944 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 166,944 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:11 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 3,834 | $5.70 | $21,853.80 |
DisclosureSEC source: 0001628280-26-023150 · wk-form4_1775160674.xml · nonDerivative · entry 4 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 101,431.071 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:11 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionCommon Stock | 11,193 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023150 · wk-form4_1775160674.xml · nonDerivative · entry 3 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,265.071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:11 UTC |
Falcione AaronChief Human Resources Officer
|
Tax withholdingCommon Stock | 2,306 | $5.70 | $13,144.20 |
DisclosureSEC source: 0001628280-26-023150 · wk-form4_1775160674.xml · nonDerivative · entry 2 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 94,072.071 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:11 UTC |
Falcione AaronChief Human Resources Officer
|
Exercise / conversionCommon Stock | 6,732 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023150 · wk-form4_1775160674.xml · nonDerivative · entry 1 Falcione Aaron · CIK 0001859803 · Chief Human Resources Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,378.071 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:07 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionRestricted Stock Units · Derivative | 8,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023143 · wk-form4_1775160473.xml · derivative · entry 7 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,790 Underlying: Common Stock · 8,394 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 25,184 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F5 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 25,184 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:07 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionRestricted Stock Units · Derivative | 4,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023143 · wk-form4_1775160473.xml · derivative · entry 6 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,606 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F4 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 13,818 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F4 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 13,818 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:07 UTC |
Nisita VittorioHead of Global Business Svcs
|
GrantRestricted Stock Units · Derivative | 125,208 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023143 · wk-form4_1775160473.xml · derivative · entry 5 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,208 Underlying: Common Stock · 125,208 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 125,208 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 125,208 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 125,208 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:07 UTC |
Nisita VittorioHead of Global Business Svcs
|
Tax withholdingCommon Stock | 2,875 | $5.70 | $16,387.50 |
DisclosureSEC source: 0001628280-26-023143 · wk-form4_1775160473.xml · nonDerivative · entry 4 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,619.158 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSUs") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:07 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionCommon Stock | 8,394 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023143 · wk-form4_1775160473.xml · nonDerivative · entry 3 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 73,494.158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:07 UTC |
Nisita VittorioHead of Global Business Svcs
|
Tax withholdingCommon Stock | 1,578 | $5.70 | $8,994.60 |
DisclosureSEC source: 0001628280-26-023143 · wk-form4_1775160473.xml · nonDerivative · entry 2 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,100.158 F1 · price: The price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSUs") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:07 UTC |
Nisita VittorioHead of Global Business Svcs
|
Exercise / conversionCommon Stock | 4,606 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023143 · wk-form4_1775160473.xml · nonDerivative · entry 1 Nisita Vittorio · CIK 0001859843 · Head of Global Business Svcs 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,678.158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:02 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 16,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · derivative · entry 7 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,580 Underlying: Common Stock · 16,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: On March 31, 2025, the Reporting Person was granted 50,369 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. F5 · derivative.expiration_date: On March 31, 2025, the Reporting Person was granted 50,369 RSUs. One-third of such RSUs vested on March 31, 2026, with the remaining two-thirds to vest on March 31, 2027 and March 31, 2028. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:02 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
Exercise / conversionRestricted Stock Units · Derivative | 7,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · derivative · entry 6 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,795 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F4 · derivative.exercise_date: On March 31, 2023, the Reporting Person was granted 23,384 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. F4 · derivative.expiration_date: On March 31, 2023, the Reporting Person was granted 23,384 RSUs. Two-thirds of such RSUs previously vested, and the remaining one-third vested on March 31, 2026. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:02 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
GrantRestricted Stock Units · Derivative | 333,889 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · derivative · entry 5 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,889 Underlying: Common Stock · 333,889 shares Expires not disclosed F2 · derivative.exercise_price: On March 31, 2026, the Reporting Person was granted 333,889 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.exercise_date: On March 31, 2026, the Reporting Person was granted 333,889 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. F2 · derivative.expiration_date: On March 31, 2026, the Reporting Person was granted 333,889 RSUs, with each RSU representing a contingent right to receive one share of Organon common stock. These RSUs will vest and become exercisable in three equal installments on March 31, 2027, March 31, 2028, and March 31, 2029. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:02 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
Tax withholdingCommon Stock | 4,784 | $5.70 | $27,268.80 |
DisclosureSEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · nonDerivative · entry 4 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 123,122.923 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:02 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
Exercise / conversionCommon Stock | 16,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · nonDerivative · entry 3 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 127,906.923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:02 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
Tax withholdingCommon Stock | 2,221 | $5.70 | $12,659.70 |
DisclosureSEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · nonDerivative · entry 2 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,117.923 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Monday, March 30, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:02 UTC |
Morrissey Joseph T. Jr.Interim CEO
|
Exercise / conversionCommon Stock | 7,795 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-023127 · wk-form4_1775160158.xml · nonDerivative · entry 1 Morrissey Joseph T. Jr. · CIK 0001859805 · Interim CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,338.923 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:10 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
Exercise / conversionRestricted Stock Units · Derivative | 7,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022397 · wk-form4_1774987834.xml · derivative · entry 3 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,979 Underlying: Common Stock · 7,979 shares Expires 2027-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F3 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F3 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:10 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
Tax withholdingCommon Stock | 2,733 | $5.84 | $15,960.72 |
DisclosureSEC source: 0001628280-26-022397 · wk-form4_1774987834.xml · nonDerivative · entry 2 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,420.703 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:10 UTC |
Drinane Juliana PapaInterim Head of Mfg & Supply
|
Exercise / conversionCommon Stock | 7,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022397 · wk-form4_1774987834.xml · nonDerivative · entry 1 Drinane Juliana Papa · CIK 0002096406 · Interim Head of Mfg & Supply 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,153.703 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:15 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
Exercise / conversionRestricted Stock Units · Derivative | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022421 · wk-form4_1774988138.xml · derivative · entry 3 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,319 Underlying: Common Stock · 5,319 shares Expires 2027-03-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU converts into one share of Organon common stock. F4 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F4 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:15 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
Tax withholdingCommon Stock | 1,516 | $5.84 | $8,853.44 |
DisclosureSEC source: 0001628280-26-022421 · wk-form4_1774988138.xml · nonDerivative · entry 2 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,561.427 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. F2 · balance_after: Includes the addition of 82 shares of Organon common stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:15 UTC |
Holzbaur LynetteSVP and Corporate Controller
|
Exercise / conversionCommon Stock | 5,319 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022421 · wk-form4_1774988138.xml · nonDerivative · entry 1 Holzbaur Lynette · CIK 0002068746 · SVP and Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,995.427 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:12 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionRestricted Stock Units · Derivative | 7,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022410 · wk-form4_1774987975.xml · derivative · entry 3 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,757 Underlying: Common Stock · 7,757 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F3 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F3 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:12 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Tax withholdingCommon Stock | 2,210 | $5.84 | $12,906.40 |
DisclosureSEC source: 0001628280-26-022410 · wk-form4_1774987975.xml · nonDerivative · entry 2 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,401.163 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 16:12 UTC |
Weaver KirkeGen. Counsel & Corp. Secy.
|
Exercise / conversionCommon Stock | 7,757 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022410 · wk-form4_1774987975.xml · nonDerivative · entry 1 Weaver Kirke · CIK 0001959622 · Gen. Counsel & Corp. Secy. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,611.163 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:09 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionRestricted Stock Units · Derivative | 8,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022387 · wk-form4_1774987760.xml · derivative · entry 3 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,865 Underlying: Common Stock · 8,865 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F5 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F5 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:09 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Tax withholdingCommon Stock | 3,181 | $5.84 | $18,577.04 |
DisclosureSEC source: 0001628280-26-022387 · wk-form4_1774987760.xml · nonDerivative · entry 2 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,436.477 F2 · price: This price is the closing market price of Organon common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. F3 · balance_after: Includes the addition of 708.122 shares of Organon common stock acquired from dividend equivalents net of withholding tax not previously required to be reported. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:09 UTC |
Arjona Ferreira Juan CamiloHead of R&D & CMO
|
Exercise / conversionCommon Stock | 8,865 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022387 · wk-form4_1774987760.xml · nonDerivative · entry 1 Arjona Ferreira Juan Camilo · CIK 0001714080 · Head of R&D & CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,909.355 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: The total number of shares reported as beneficially owned has been reduced to reflect 13,872 shares of Organon & Co. ("Organon") common stock transferred pursuant to an exemption under Exchange Act Rule 16a-12. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:06 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionRestricted Stock Units · Derivative | 15,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022377 · wk-form4_1774987616.xml · derivative · entry 3 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,071 Underlying: Common Stock · 15,071 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Organon common stock. F3 · derivative.exercise_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. F3 · derivative.expiration_date: These RSUs vest and are distributed as shares of Organon common stock in three equal installments on March 29, 2025, March 29, 2026, and March 29, 2027. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:06 UTC |
WALSH MATTHEW MChief Financial Officer
|
Tax withholdingCommon Stock | 5,162 | $5.84 | $30,146.08 |
DisclosureSEC source: 0001628280-26-022377 · wk-form4_1774987616.xml · nonDerivative · entry 2 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,660 F1 · price: This price is the closing market price of Organon & Co. ("Organon") common stock on Friday, March 27, 2026, as required by the plan under which the Restricted Stock Units ("RSU") were awarded. Read SEC document |
| March 29, 2026 Filed Mar 31, 2026 20:06 UTC |
WALSH MATTHEW MChief Financial Officer
|
Exercise / conversionCommon Stock | 15,071 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-022377 · wk-form4_1774987616.xml · nonDerivative · entry 1 WALSH MATTHEW M · CIK 0001269428 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 195,822 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.